Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

Researchers suggest hybrid convalescent plasma therapy neutralizes the omicron variant

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

SARS-CoV-2 Omicron variant neutralized by third BNT162b2 booster shot

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

New study suggests most monoclonal antibody treatments are ineffective against Omicron SARS-CoV-2 variant

A test to identify antibody effectiveness against COVID-19 variants

A test to identify antibody effectiveness against COVID-19 variants

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

Anti-SARS-CoV-2 antibody infusion shown to demonstrate robust immune response following COVID-19 vaccination

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

New study demonstrates SARS-CoV-2 Omicron antibody escape

New study demonstrates SARS-CoV-2 Omicron antibody escape

Human monoclonal antibody protects against SARS-CoV-2 and SARS-CoV in vivo

Human monoclonal antibody protects against SARS-CoV-2 and SARS-CoV in vivo

Evaluation of SARS-CoV-2 Omicron's immune evasion potential

Evaluation of SARS-CoV-2 Omicron's immune evasion potential

Hyperbaric oxygen treatment quickly resolves severe breathing difficulties in COVID-19 patients

Hyperbaric oxygen treatment quickly resolves severe breathing difficulties in COVID-19 patients

Monoclonal antibody activity against SARS-CoV-2 Omicron variant

Monoclonal antibody activity against SARS-CoV-2 Omicron variant

Providing quick & efficient CRO services with Sino Biological

Providing quick & efficient CRO services with Sino Biological

Researchers develop a universal SARS-CoV-2 neutralizing antibody

Researchers develop a universal SARS-CoV-2 neutralizing antibody

New tool to help map immune escape with SARS-CoV-2 mutations

New tool to help map immune escape with SARS-CoV-2 mutations

Indication of minor added benefit of nivolumab for adjuvant treatment of esophageal cancer

Indication of minor added benefit of nivolumab for adjuvant treatment of esophageal cancer

Biologic agent dupilumab effective in improving asthma exacerbations and lung function, study shows

Biologic agent dupilumab effective in improving asthma exacerbations and lung function, study shows

Thousands of the UK’s most vulnerable people to receive cutting-edge COVID-19 treatments at home

Thousands of the UK’s most vulnerable people to receive cutting-edge COVID-19 treatments at home

Rapid antigen detection test for SARS-CoV-2 proves more effective than expected, large study reports

Rapid antigen detection test for SARS-CoV-2 proves more effective than expected, large study reports

Possible impact of spike protein mutations on SARS-CoV-2 Omicron variant

Possible impact of spike protein mutations on SARS-CoV-2 Omicron variant

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.